Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124847632 | 12484763 | 2 | F | 2015 | 20160801 | 20160621 | 20160812 | EXP | CA-HQ SPECIALTY-CA-2016INT000390 | INTERCHEM | 52.00 | YR | F | Y | 0.00000 | 20160812 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124847632 | 12484763 | 1 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 2.1429 MG (15 MG,1 IN 1 W) | 201749 | 15 | MG | ||||||||
| 124847632 | 12484763 | 2 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 2.1429 MG (15 MG,1 IN 1 W) | 201749 | 15 | MG | ||||||||
| 124847632 | 12484763 | 3 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 10 MG (5 MG,2 IN 1 D) | 0 | 5 | MG | ||||||||
| 124847632 | 12484763 | 4 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 10 MG (5 MG,2 IN 1 D) | 0 | 5 | MG | ||||||||
| 124847632 | 12484763 | 5 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 10 MG (5 MG,2 IN 1 D) | 0 | 5 | MG | ||||||||
| 124847632 | 12484763 | 6 | SS | ATASOL | ACETAMINOPHEN | 1 | Unknown | AS NECESSARY | 0 | ||||||||||
| 124847632 | 12484763 | 7 | SS | ATASOL | ACETAMINOPHEN | 1 | Unknown | RESUMED (AS NECESSARY) | 0 | ||||||||||
| 124847632 | 12484763 | 8 | SS | NAPROSYN | NAPROXEN | 1 | Unknown | UNK | 0 | ||||||||||
| 124847632 | 12484763 | 9 | SS | NAPROSYN | NAPROXEN | 1 | Unknown | 2 IN 1 D | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124847632 | 12484763 | 1 | Rheumatoid arthritis |
| 124847632 | 12484763 | 3 | Rheumatoid arthritis |
| 124847632 | 12484763 | 6 | Pain |
| 124847632 | 12484763 | 8 | Pain |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124847632 | 12484763 | OT |
| 124847632 | 12484763 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124847632 | 12484763 | Chromaturia | |
| 124847632 | 12484763 | Diarrhoea | |
| 124847632 | 12484763 | Dysuria | |
| 124847632 | 12484763 | Eye pain | |
| 124847632 | 12484763 | Fatigue | |
| 124847632 | 12484763 | Haemorrhoids | |
| 124847632 | 12484763 | Infection | |
| 124847632 | 12484763 | Nail bed bleeding | |
| 124847632 | 12484763 | Nasopharyngitis | |
| 124847632 | 12484763 | Ocular discomfort | |
| 124847632 | 12484763 | Pollakiuria | |
| 124847632 | 12484763 | Pyrexia | |
| 124847632 | 12484763 | Rheumatoid arthritis | |
| 124847632 | 12484763 | Urinary incontinence | |
| 124847632 | 12484763 | Urine abnormality | |
| 124847632 | 12484763 | Uterine cancer | |
| 124847632 | 12484763 | Vaginal infection | |
| 124847632 | 12484763 | Vision blurred |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124847632 | 12484763 | 1 | 20160308 | 0 | ||
| 124847632 | 12484763 | 2 | 2016 | 0 | ||
| 124847632 | 12484763 | 3 | 20150821 | 20151104 | 0 | |
| 124847632 | 12484763 | 4 | 20151109 | 20160315 | 0 | |
| 124847632 | 12484763 | 5 | 2016 | 0 |